A2AR--STAT1 (Y701) -HLA-E轴作为放射治疗耐药三阴性乳腺癌中潜在的免疫调节途径
Young Shin Ko1,2, Hana Jin1, So Eun Lee1,2
1Department of Pharmacology, College of Medicine, Institute of Medical Sciences, Gyeongsang National University, Jinjudaero 816 Bungil 15, Jinju 52727, Republic of Korea.
Carcinogenesis
|October 22, 2025
概括
三阴性乳腺癌 (TNBC) 对放射治疗的耐药性与增加的HLA-E表达有关. 针对A2AR-STAT1通路,使用弗鲁达拉宾或莫纳利祖马布等药物,可以克服这种抗药性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 三重阴性乳腺癌 (TNBC) 的结果不好,放射治疗耐药性 (RT-R-TNBC) 增加了侵袭性.
- 自然杀手 (NK) 细胞对RT-R-TNBC的细胞毒性由于人类白细胞抗原类E (HLA-E) 的上调而降低.
- 识别HLA-E上调的机制对于开发TNBC的新疗法至关重要.
研究的目的:
- 阐明TNBC和RT-R-TNBC中HLA-E上调的背后机制.
- 确定潜在的治疗点,以克服TNBC中放射疗法耐药性.
- 评估向A2AR-STAT1-HLA-E轴和NK细胞介导免疫的有效性.
主要方法:
- 在TNBC和正常组织中评估HLA-E和A2AR表达.
- 利用细胞系 (MDA-MB-231,RT-R-MDA-MB-231) 来研究A2AR和STAT1在HLA-E表达和NK细胞细胞毒性的作用.
- 在试验室和体内小鼠模型中给药了fludarabine (STAT1抑制剂) 和monalizumab (NKG2A抗体).
主要成果:
- 在TNBC组织中,HLA-E表达与A2AR水平正相关.
- 通过A2AR和STAT1的淘汰,恢复了NK细胞对TNBC细胞的细胞毒性.
- 弗鲁达拉宾抑制了腺诱导和基底HLA-E表达,减少了瘤的进展和小鼠的转移.
- 莫纳利祖马布降低了瘤进展和转移,增加了小鼠中的细胞毒性NK细胞群.
结论:
- A2AR--STAT1 (Y701) -HLA-E通路与TNBC中的放射治疗耐药性有关.
- 针对这一轴,可能是用fludarabine或用monalizumab增强NK细胞活性,为RT-R-TNBC提供了一个有前途的治疗策略.
更多相关视频
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
The JAK-STAT Signaling Pathway
12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.0K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


